Novel mRNA vaccine shows promise against deadly brain cancer

A new mRNA cancer vaccine activates the immune system against glioblastoma, showing promising results in preclinical models and an initial human trial with four patients. The vaccine utilizes lipid nanoparticles containing personalized tumor cells, rapidly turning 'cold' tumors 'hot'. The research, starting with successful outcomes in mice and pet dogs, progresses to expanded Phase I clinical trials. The breakthrough offers hope for treating notoriously resistant cancers.